PHIA Stock Analysis: Koninklijke Philips | AS
Medical Devices | AS, Netherlands | Market Cap: 23.998m EUR | 12M Return: 18% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 44.0M
EPS Trend: 28.8%
Qual. Beats: 0
Rev. Trend: -95.2%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Koninklijke Philips N.V. (PHIA) is a Dutch health technology company founded in 1891 and headquartered in Amsterdam. It operates through three segments: Diagnosis & Treatment (covering diagnostic imaging such as ultrasound, MRI, CT, and X-ray, as well as image-guided therapy systems), Connected Care (monitoring, enterprise informatics, and sleep and respiratory care), and Personal Health (consumer health products). The company is active in North America, Greater China, and other international markets, and maintains a strategic alliance with WellSpan Health focused on advanced imaging and diagnostics.
The company was renamed from Koninklijke Philips Electronics N.V. to its current name in May 2013, reflecting its strategic shift away from consumer electronics and toward health technology. The medical equipment industry in which Philips operates is characterized by high regulatory barriers (FDA, CE marking), long product development cycles, and significant ongoing R&D investment, with demand typically driven by hospital capital expenditure, aging populations, and the digitization of healthcare delivery.
- Respironics CPAP recall settlement clears multi-year legal overhang
- Diagnostic Imaging orders accelerate, boosting Diagnosis & Treatment segment revenue
- China healthcare spending weakness pressures emerging markets revenue growth
| Net Income: 970.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 6.49 > 1.0 |
| NWC/Revenue: 13.34% < 20% (prev 10.63%; Δ 2.70% < -1%) |
| CFO/TA 0.08 > 3% & CFO 2.29b > Net Income 970.0m |
| Net Debt (6.47b) to EBITDA (2.72b): 2.38 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (968.5m) vs 12m ago 3.24% < -2% |
| Gross Margin: 45.20% > 18% (prev 43.42%; Δ 1.78% > 0.5%) |
| Asset Turnover: 64.82% > 50% (prev 66.18%; Δ -1.36% > 0%) |
| Interest Coverage Ratio: 4.88 > 6 (EBIT TTM 1.60b / Interest Expense TTM 329.0m) |
| A: 0.09 (Total Current Assets 9.78b - Total Current Liabilities 7.43b) / Total Assets 27.3b |
| B: 0.14 (Retained Earnings 3.71b / Total Assets 27.3b) |
| C: 0.06 (EBIT TTM 1.60b / Avg Total Assets 27.2b) |
| D: 0.72 (Book Value of Equity 11.4b / Total Liabilities 15.8b) |
| Altman-Z'' = 2.16 = BBB |
| DSRI: 0.97 (Receivables 3.31b/3.48b, Revenue 17.6b/18.0b) |
| GMI: 0.96 (GM 43.42% / 45.20%) |
| AQI: 0.95 (AQ_t 0.56 / AQ_t-1 0.59) |
| SGI: 0.98 (Revenue 17.6b / 18.0b) |
| TATA: -0.05 (NI 970.0m - CFO 2.29b) / TA 27.3b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at EUR 24.06 with a total of 969,727 shares traded. Over the past week, the price has changed by -2.55%, over one month by +7.12%, over three months by +2.95% and over the past year by +18.03%.
Current recommended Stop Loss: 22.50 (which is 6.5% or 2.9 ATR below the current price).
Koninklijke Philips has no consensus analysts rating.
P/E Trailing = 24.69
P/E Forward = 15.528
P/S = 1.3603
P/B = 2.0665
P/EG = 0.9241
Revenue TTM = 17.6b EUR
EBIT TTM = 1.60b EUR
EBITDA TTM = 2.72b EUR
Long Term Debt = 6.89b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.21b EUR (from shortTermDebt, last quarter)
Debt = 9.06b EUR (from shortLongTermDebtTotal, last quarter) + Leases 964.0m
Net Debt = 6.47b EUR (calculated: Debt 9.06b - CCE 2.59b)
Enterprise Value = 30.5b EUR (24.0b + Debt 9.06b - CCE 2.59b)
Interest Coverage Ratio = 4.88 (Ebit TTM 1.60b / Interest Expense TTM 329.0m)
EV/FCF = 15.95x (Enterprise Value 30.5b / FCF TTM 1.91b)
FCF Yield = 6.27% (FCF TTM 1.91b / Enterprise Value 30.5b)
FCF Margin = 10.83% (FCF TTM 1.91b / Revenue TTM 17.6b)
Net Margin = 5.50% (Net Income TTM 970.0m / Revenue TTM 17.6b)
Gross Margin = 45.20% ((Revenue TTM 17.6b - Cost of Revenue TTM 9.67b) / Revenue TTM)
Gross Margin QoQ = 45.20% (prev 44.89%)
Tobins Q-Ratio = 1.12 (Enterprise Value 30.5b / Total Assets 27.3b)
Interest Expense / Debt = 3.63% (Interest Expense 329.0m / Debt 9.06b)
Taxrate = 23.58% (299.0m / 1.27b)
NOPAT = 1.23b (EBIT 1.60b * (1 - 23.58%))
Current Ratio = 1.32 (Total Current Assets 9.78b / Total Current Liabilities 7.43b)
Debt / Equity = 0.80 (Debt 9.06b / totalStockholderEquity, last quarter 11.4b)
Debt / EBITDA = 2.38 (Net Debt 6.47b / EBITDA 2.72b)
Debt / FCF = 3.39 (Net Debt 6.47b / FCF TTM 1.91b)
Total Stockholder Equity = 10.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.56% (Net Income 970.0m / Total Assets 27.3b)
RoE = 8.96% (Net Income TTM 970.0m / Total Stockholder Equity 10.8b)
RoCE = 9.06% (EBIT 1.60b / Capital Employed (Equity 10.8b + L.T.Debt 6.89b))
RoIC = 6.08% (NOPAT 1.23b / Invested Capital 20.2b)
WACC = 6.13% (E(24.0b)/V(33.1b) * Re(7.40%) + D(9.06b)/V(33.1b) * Rd(3.63%) * (1-Tc(0.24)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 1.32%
[DCF] Terminal Value 77.97% ; FCFF base≈1.20b ; Y1≈1.38b ; Y5≈2.03b
[DCF] Fair Price = 24.75 (EV 30.5b - Net Debt 6.47b = Equity 24.1b / Shares 972.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 28.75 | EPS CAGR: 73.29% | SUE: 0.08 | # QB: 0
Revenue Correlation: -95.20 | Revenue CAGR: -1.45% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.34 | Chg30d=-2.44% | Revisions=-50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.39 | Chg30d=+0.23% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=1.53 | Chg30d=-0.20% | Revisions=+17% | GrowthEPS=-1.9% | GrowthRev=+0.9%
EPS next Year (2027-12-31): EPS=1.71 | Chg30d=-0.14% | Revisions=-17% | GrowthEPS=+11.7% | GrowthRev=+4.5%
[Analyst] Revisions Ratio: -15% (up=4, down=6)